Previous Close | 6.24 |
Open | 6.24 |
Bid | 5.93 x 400 |
Ask | 6.05 x 400 |
Day's Range | 5.96 - 6.49 |
52 Week Range | 1.57 - 8.19 |
Volume | |
Avg. Volume | 199,872 |
Market Cap | 260.951M |
Beta (5Y Monthly) | 0.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Werewolf Therapeutics ( NASDAQ:HOWL ) Full Year 2023 Results Key Financial Results Revenue: US$19.9m (up 22% from FY...